Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Waldschmidt

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Haematologica|April 21, 2018
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)Johannes M Waldschmidt, Alexander Keller, Gabriele Ihorst, et al.
Annals of Hematology|December 20, 2023
Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myelomaC Riedhammer, J Düll, C Kestler, et al.
Frontiers in Oncology|January 31, 2025
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibitionJohannes M Waldschmidt, Lukas Haug, Christine Riedhammer, et al.
Blood Advances|January 15, 2025
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myelomaJohannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Cancer Immunology Research|June 27, 2022
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell TherapyNam Gyu Im, Amy Guillaumet-Adkins, Megha Wal, et al.
Haematologica|April 4, 2024
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Haematologica|November 4, 2024
<i>Erratum</i> to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Hemasphere|January 24, 2025
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple MyelomaXiang Zhou, Annika Hofmann, Benedict Engel, et al.
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
Haematologica|January 8, 2026
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myelomaSeungbin Han, Umair Munawar, Marietta Truger, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Haematologica|April 21, 2018
Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)Johannes M Waldschmidt, Alexander Keller, Gabriele Ihorst, et al.
Annals of Hematology|December 20, 2023
Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myelomaC Riedhammer, J Düll, C Kestler, et al.
Frontiers in Oncology|January 31, 2025
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibitionJohannes M Waldschmidt, Lukas Haug, Christine Riedhammer, et al.
Blood Advances|January 15, 2025
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myelomaJohannes M Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Cancer Immunology Research|June 27, 2022
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell TherapyNam Gyu Im, Amy Guillaumet-Adkins, Megha Wal, et al.
Haematologica|April 4, 2024
Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Haematologica|November 4, 2024
<i>Erratum</i> to: Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myelomaUmair Munawar, Johanna Theuersbacher, Maximilian J Steinhardt, et al.
Hemasphere|January 24, 2025
Combining SKY92 gene expression profiling and FISH (according to R2-ISS) defines ultra-high-risk Multiple MyelomaXiang Zhou, Annika Hofmann, Benedict Engel, et al.
Nature Cell Biology|October 22, 2021
Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myelomaJulia Frede, Praveen Anand, Noori Sotudeh, et al.
Haematologica|January 8, 2026
Promoter hypermethylation as a reversible mechanism of resistance to GPRC5D-directed therapy in multiple myelomaSeungbin Han, Umair Munawar, Marietta Truger, et al.
Pageof 7